The immunoinformatics of cancer immunotherapy

Tissue Antigens

Volumn 70, Issue 4, 2007, Pages 265-271

  DeLuca, D S ^a   Blasczyk, R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antigen presentation; Immunoinformatics; Immunotherapy

Indexed keywords

CANCER ANTIBODY; MINOR HISTOCOMPATIBILITY ANTIGEN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ANTIGEN PRESENTATION; BIOINFORMATICS; CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; CANCER VACCINES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 34548370670     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2007.00914.x     Document Type: Review

References (73)

1. Yee C. Adoptive T cell therapy: addressing challenges in cancer immunotherapy. J Transl Med 2005 : 3 : 17.
2. Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother 2006 : 55 : 96 103.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001 : 411 : 380 4.
4. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003 : 21 : 2415 32.
5. Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002 : 20 : 143 8.
6. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003 : 9 : 619 24.
7. Yee C, Gilbert MJ, Riddell SR et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 1996 : 157 : 4079 86.
8. Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002 : 99 : 16168 73.
9. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000 : 75 : 235 82.
10. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996 : 2 : 52 8.
11. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998 : 4 : 328 32.
12. Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999 : 80 : 219 30.
13. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999 : 190 : 1669 78.
14. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997 : 9 : 139 45.
15. Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol 2000 : 12 : 576 82.
16. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999 : 10 : 281 7.
17. Brusic V, Petrovsky N. Immunoinformatics - the new kid in town. Novartis Found Symp 2003 : 254 : 3 13 discussion 13-22, 98-101, 250-2.
18. Tenzer S, Peters B, Bulik S et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 2005 : 62 : 1025 37.
19. Doytchinova IA, Guan P, Flower DR. EpiJen: a server for multistep T cell epitope prediction. BMC Bioinformatics 2006 : 7 : 131.
20. Larsen MV, Lundegaard C, Lamberth K et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 2005 : 35 : 2295 303.
21. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997 : 9 : 684 93.
22. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 1991 : 66 : 1145 53.
23. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol 2005 : 17 : 202 10.
24. Barrett AJ, van Rhee F. Graft-versus-leukaemia. Baillieres Clin Haematol 1997 : 10 : 337 55.
25. Halling-Brown M, Quartey-Papafio R, Travers PJ, Moss DS. SiPep: a system for the prediction of tissue-specific minor histocompatibility antigens. Int J Immunogenet 2006 : 33 : 289 95.
26. Schuler MM, Donnes P, Nastke MD, Kohlbacher O, Rammensee HG, Stevanovic S. SNEP: sNP-derived epitope prediction program for minor H antigens. Immunogenetics 2005 : 57 : 816 20.
27. Pamer E, Cresswell P. Mechanisms of MHC class I -restricted antigen processing. Annu Rev Immunol 1998 : 16 : 323 58.
28. Emmerich NP, Nussbaum AK, Stevanovic S et al. The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J Biol Chem 2000 : 275 : 21140 8.
29. Toes RE, Nussbaum AK, Degermann S et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001 : 194 : 1 12.
30. Tenzer S, Stoltze L, Schonfisch B et al. Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J Immunol 2004 : 172 : 1083 91.
31. Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci U S A 1997 : 94 : 10850 5.
32. Serwold T, Gaw S, Shastri N. ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat Immunol 2001 : 2 : 644 51.
33. Barnea E, Beer I, Patoka R et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol 2002 : 32 : 213 22.
34. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004 : 19 : 216 24.
35. van Endert PM, Riganelli D, Greco G et al. The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 1995 : 182 : 1883 95.
36. Uebel S, Kraas W, Kienle S, Wiesmuller KH, Jung G, Tampe R. Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. Proc Natl Acad Sci U S A 1997 : 94 : 8976 81.
37. Scholz C, Tampe R. The intracellular antigen transport machinery TAP in adaptive immunity and virus escape mechanisms. J Bioenerg Biomembr 2005 : 37 : 509 15.
38. Gubler B, Daniel S, Armandola EA, Hammer J, Caillat-Zucman S, van Endert PM. Substrate selection by transporters associated with antigen processing occurs during peptide binding to TAP. Mol Immunol 1998 : 35 : 427 33.
39. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhutter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 2003 : 171 : 1741 9.
40. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999 : 17 : 51 88.
41. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994 : 152 : 163 75.
42. Rognan. Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes. Biochemistry 1994 : 33 : 11476 86.
43. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999 : 50 : 213 9.
44. Rognan D, Lauemoller SL, Holm A, Buus S, Tschinke V. Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. J Med Chem 1999 : 42 : 4650 8.
45. Buus S, Lauemoller SL, Worning P et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003 : 62 : 378 84.
46. Nielsen M, Lundegaard C, Worning P et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003 : 12 : 1007 17.
47. Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004 : 56 : 405 19.
48. DeLuca DS, Khattab B, Blasczyk R. A modular concept of HLA for comprehensive peptide binding prediction. Immunogenetics 2007 : 59 : 25 35.
49. Disis ML, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 1998 : 18 : 37 45.
50. Lu J, Celis E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res 2000 : 60 : 5223 7.
51. Rongcun Y, Salazar-Onfray F, Charo J et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999 : 163 : 1037 44.
52. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998 : 188 : 2357 68.
53. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998 : 188 : 2199 204.
54. Brusic V, Rudy G, Honeyman G, Hammer J, Harrison L. Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 1998 : 14 : 121 30.
55. Marshall KW, Wilson KJ, Liang J, Woods A, Zaller D, Rothbard JB. Prediction of peptide affinity to HLA DRB1*0401. J Immunol 1995 : 154 : 5927 33.
56. Yu K, Petrovsky N, Schonbach C, Koh JY, Brusic V. Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol Med 2002 : 8 : 137 48.
57. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996 : 334 : 281 5.
58. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003 : 197 : 1279 89.
59. Fruci D, Lauvau G, Saveanu L et al. Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J Immunol 2003 : 170 : 2977 84.
60. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986 : 234 : 179 86.
61. Kessler JH, Beekman NJ, Bres-Vloemans SA et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001 : 193 : 73 88.
62. Paston SJ, Dodi IA, Madrigal JA. Progress made towards the development of a CMV peptide vaccine. Hum Immunol 2004 : 65 : 544 9.
63. Chan CC, Stark J, George AJ. Analysis of cytokine dynamics in corneal allograft rejection. Proc Biol Sci 1999 : 266 : 2217 23.
64. Forrest S, Beauchemin C. Computer immunology. Immunol Rev 2007 : 216 : 176 97.
65. Nielsen M, Lundegaard C, Lund O, Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005 : 57 : 33 41.
66. Peters B, Sidney J, Bourne P et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005 : 3 : e91.
67. Doytchinova IA, Flower DR. Class I T-cell epitope prediction: improvements using a combination of proteasome cleavage, TAP affinity, and MHC binding. Mol Immunol 2006 : 43 : 2037 44.
68. Doytchinova I, Hemsley S, Flower DR. Transporter associated with antigen processing preselection of peptides binding to the MHC: a bioinformatic evaluation. J Immunol 2004 : 173 : 6813 9.
69. Guan P, Hattotuwagama CK, Doytchinova IA, Flower DR. MHCPred 2.0: an updated quantitative T-cell epitope prediction server. Appl Bioinformatics 2006 : 5 : 55 61.
70. Bhasin M, Raghava GP. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes. J Biosci 2007 : 32 : 31 42.
71. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993 : 75 : 693 708.
72. Groll M, Ditzel L, Lowe J et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997 : 386 : 463 71.
73. Gaudet R, Wiley DC. Structure of the ABC ATPase domain of human TAP1, the transporter associated with antigen processing. EMBO J 2001 : 20 : 4964 72.